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Abstract
In inverse planning of lung radiotherapy, techniques are required to ensure dose cov-
erage of target disease in the presence of tumor motion as a result of respiration. A
range of published techniques for mitigating motion effects were compared for dose
stability across 5 breath cycles of 2 cm. Techniques included planning target volume
(PTV) expansions, internal target volumes with (OITV) and without tissue override
(ITV), average dataset scans (ADS), and mini-max robust optimization. Volumetric arc
therapy plans were created on a thorax phantom and verified with chamber and film
measurements. Dose stability was compared by DVH analysis in calculations across all
geometries. The lung override technique resulted in a substantial lack of dose cover-
age (10%) to the tumor in the presence of large motion. PTV, ITV and ADS tech-
niques resulted in substantial (up to 25%) maximum dose increases where solid tissue
travelled into low density optimized regions. The results highlight the need for care in
optimization of highly heterogeneous where density variations may occur with
motion. Robust optimization was shown to provide greater stability in both maximum
(<3%) and minimum dose variations (<2%) over all other techniques.
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1 | INTRODUCTION
Lung Cancer is the leading cause of cancer death in Australia1 whilst the
American Cancer Society records 5-year survival of lung tumor cases at
17%.2 Surgery morbidity and a need for multimodality treatments results
in over half of all lung cancer patients receiving radiotherapy as some
part of their clinical treatment.2 Volumetric Modulated Arc Radiotherapy
(VMAT) and Intensity Modulated Radiotherapy (IMRT) have been shown
to provide improvements in radiotherapy plan dose distribution over
3-Dimensional Conformal Radiotherapy Techniques (3DCRT).3,4
As a result of patient breathing, large variations in primary tumor
position are often seen during radiotherapy of lung disease. An
enormous amount of work has investigated the variations in organs
and tumors with breathing. The AAPM Task Group 765 presented
the following summation on review of the literature; “The amount a
lung tumor moves during breathing varies widely. . .There are no
general patterns of respiratory behavior that can be assumed for a
particular patient prior to observation and treatment”. Many of the
reviewed studies6–13 had focused on quantifying the magnitude of
such tumor motion, showing variations as great as 34 mm, 22 mm,
and 12 mm in the cranio-caudal, anterior-posterior, and lateral direc-
tions respectively, in some patients.14 Traditional planning methods
provide suitable coverage of mobile Gross Tumour Volumes (GTV) by
creation of Internal Target Volumes (ITV) which encompasses the GTV
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through its respiratory motion. Typically, a further expansion is made
to account for geometric set-up uncertainty of the patient, to create a
Planning Target Volume (PTV) for which dose coverage metrics are
assessed.
Recent improvements in the technology of 4-Dimensional Com-
puted Tomography (4DCT) image binning,15–18 respiratory motion
monitoring,18–23 functional imaging correlation,24–26 and faster imag-
ing techniques have resulted in several delivery methodologies to
decrease the impact of lung motion. Another approach to reducing the
impact is to minimize the motion itself by incorporating compression
belts27 to restrict diaphragm contraction and expansion, implementing
breath hold techniques23,28–30 or gating the treatment by restricting
delivery to particular components of the breathing cycle.14,20,25,31,32
Recent works from several research groups have also investigated the
tracking of tumor by dynamic correction of MLC positions.33–37 In the
majority of these solutions the objective is to minimize the ITV vol-
ume, and thus the PTV volume. Whilst some of the systems, as individ-
ual or combined solutions, are showing promising results in reduction
in irradiated volumes and healthy tissue doses,14,23,28,38 they provide a
solution to only one half of the motion induced problem.
Calculation and delivery of modulated distributions on moving
targets are subject to three well documented uncertainties between
planning and delivery; blurring, interplay, and dose deformation.
McCarter and Beckham39 demonstrated large delivery variations
in high dose gradient regions in the presence of tumor motion as a
result of the blurring effect. Several authors40,41 have shown that
extreme dose variations of up to 100% in IMRT field delivery due to
the interplay effect are theoretically possible. Subsequent statistical
analysis by Bortfeld42 found no significant difference over long course
treatments (>10 fractions) however, comparisons were made against
an introduced formalism rather than a CT dose distribution (of which
variations of up to 20% were noted). A study by Englesman et al.43
focused on dose deformation showed small variations (<5%) in dose
distributions with tumor motion and a broadening of the high dose dis-
tribution along the axis of travel with 3D conformal planning.
Optimization is the computerization of mathematical problem
solving. In the realm of radiotherapy planning the specific problem is
the maximization of dose to a target volume whilst minimizing the
dose to the surrounding tissue. By this definition a large component
of the optimization process is ensuring a minimum dose to the vox-
els encompassed by a defined target volume.
A fourth potential issue in mobile lung disease is the impact of
dose optimization to lung tissue and bronchial airways in the pres-
ence of tumor motion, where the objective function is required to
ensure target dose coverage to large PTVs that include a volume of
lung or air with a density significantly less than the GTV tissue.
Previous literature44,45 has shown the adverse dosimetric impli-
cations of optimizing to and outside of surface contours, where the
lack of electron density results in high photon fluence to achieve
equivalent doses. In such cases when the patient tissue traverses
into the region containing air during treatment, the high intensity flu-
ence results in a sharp increase in primary interactions, liberated sec-
ondary electron generation, and resultant dose deposition.46,47
In the situation of internal lung tissue the effect is less studied.
The electron densities among air, lung, and muscle tissue is similar48
suggesting the effect is predominantly the result of physical density.
It thus follows that an equivalent but reduced effect may be
observed in lung/disease boundaries. In lung patients the result of
this effect is complicated by a couple of further considerations;
1. Incident beams on lung tumors will undergo primary attenuation
and build-up of secondary electrons by superficial tissue, such as
the muscles of the chest wall. These secondary electrons are of
an order of magnitude less for surface optimization.
2. The movement is not limited to the target itself but can also
include the surrounding tissue with no necessary correlation in
direction or magnitude of motion.
Robust optimization is a recent introduction into the world of
radiotherapy planning made possible by the increased parallel com-
putational power of Graphic Processer Units (GPUs) along with more
efficient threaded allocation of dose computations. Robust optimiza-
tion allows a plan to be optimized such that it meets planning crite-
ria in not only the planning geometry, but also in given patient and
disease position variations.45 The commercial system used in this
paper is Raystation v5.0.1 (Raysearch, Sweden).
Raystation ensures robust planning doses by the incorporation
of min-max optimization whereby the geometric uncertainties of
the plan are incorporated in the problem function. The formalism
includes no dependence on a probability distribution of the poten-
tial geometric uncertainty as per Bortfeld et al.,49 Chu et al.,50
Chan et al.,51 and Olafsson and Wright,52 but rather minimizes the
objective function of the worst preforming geometry within the
included distribution. This ensures a minimum level of plan quality,
but results in a dependence on limitations of uncertainty and the
potential for the system to over optimize low probability scenarios
at the cost of plan quality of higher probability scenarios. In a
paper by Fredriksson,53 in which the formalism was introduced, the
method was shown to provide robust plans with increased lung
sparing over PTV expansions for intensity modulated proton ther-
apy, whilst work by Byrne et al45 has demonstrated its potential in
IMRT planning. The implementation of min-max optimization by
the vendor is provided in two options; specified 3-dimensional off-
sets set by the user or planning over a range of patient scans
(Fig. 1).
The aim of this work is to establish the accuracy of the Raystation
collapsed cone convolution algorithm in calculations across multiple
datasets and to utilize this methodology to analyse the suitability of
various optimization schemes in ensuring accurate and uniform dose
to moving targets through breathing cycles in lung tissue.
2 | METHOD
2.A | Datasets
Planning CT scans were taken with the CIRS thoracic phantom (CIRS
Inc., Virginia, USA) with a set of custom made wax (average density
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0.95 g/cm3) inserts. All scans were performed on an AS Definition CT
scanner (Siemens Healthcare, Erlangen) at a maximum tube energy of
120 kVp, 216 mAs at 2 mm slices. Two separate wax inserts were
used. The first wax insert was created with a chamber plug for an Exra-
din A1SL chamber (Standard Imaging, Wisconsin, USA), whilst the sec-
ond insert included a Gafchromic film holder in the sagittal plane. The
phantom was scanned in a breath cycle acquisition of five for each of
the two chamber inserts, resulting in a total of 10 scans. It should be
noted that the acquisitions were not true 4D binning, and had no time
correlation. To emulate binned breathing the scans were taken with
the phantom in an identical location but with the wax inserts manually
translated in 1 cm increments from 2 cm inferior of the planning scan
(0 cm offset) to 2 cm superior to the planning scan. For clarity the
individual scans will be referred to by their offsets and collectively
group referred to as the breathing cycle. In each of the CT scans of the
film inserts, a dummy film was included to ensure the planning density
matched that used for film exposures. This particular study is inter-
ested in the effect of optimizing to lung. To assess the extent of the
effect the phantom insert region above the inserts was left as air, as
demonstrated in Fig. 2.
For both the chamber and film cases the scans included the cen-
tral planning position and two superior and inferior offset scans of
1 cm and 2 cm. Visual examples of the translations are shown in
Fig. 2.
For each of the 4DCT sets an “average” scan was created in
RayStation whereby the Hounsfield units of all five scans are sum-
mated and averaged on to a 6th dataset. This was included to allow
for the assessment of the potential use of this simpler and faster
technique to account for varying geometry densities.
An example of each of the datasets are shown in Fig. 3 along
with an example of the average dataset at the end. The sagittal ori-
entation is shown for clarity of the average effect.
2.B | Breathing cycles and plan parameters
All breathing cycle scans were imported into the Raystation sys-
tem as 4DCT groups. Geometric contours representing the heart,
left and right lungs, spinal cord and ribs were propagated across
all datasets. The target volume was defined as GTV in each data-
set individually, and an ITV was created as a summation of all
GTVs registered back to the primary central dataset. A uniform
expansion of 0.5 cm was applied to the GTV/ITV to create a
PTV in each case. The margin was selected as per clinical proto-
col to account for imaging set-up tolerances. All tumor motion
margin was assumed to be included in the robust method incor-
porated.
To promote conformal dose distributions and to correlate with
typical planning convention a ring geometry was created around
the target ITV volume. An example of the target geometries is
shown in Fig. 3, inclusive of a demonstration of the average
4DCT scan.
A set of plans were created for both the chamber dataset and
film dataset, and are individually outlined below;
1. Plan ITV: Optimization was performed to ensure minimum dose
to the full extent of the GTV travel. An ITV was created by sum-
mation of the GTV across all scans and a 5 mm PTV expansion
applied in all orthogonal planes, inclusive of the air volume supe-
riorly and lung volume inferiorly.
F I G . 1 . Robust optimization incorporation in Raystation using positional uncertainty (left) and multiple image sets (right).
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2. Plan GTV: Plan was optimized to the GTV in the central axis with
a PTV expansion of 5 mm. It is expected that this will result in
minimum coverage failures throughout the breathing cycle. This
further highlights effects of edge of border effects at lung/tissue
boundaries and expected dosimetry in a reduced phase treat-
ment, such as gating.
3. Plan average: Plan was optimized to the ITV + 5 mm on an aver-
age dataset where the travel of the inserts resulted in a lower
density at the central GTV position, but a spread medium density
along the full length of travel. The volume was mapped to the
average dataset by static registration to ensure comparable plan-
ning volumes. This technique has been proposed previously in
the literature.54,55 It should be noted that the average dataset
approach does not consider the respective time component of
each phase, but purely averages across all five scans. Thus, an
area that is air in four of five scans and tissue of density
1.0 g/cm3 in the 5th will result in an average CT density of the
voxel of 0.2 g/cm3.
4. Plan robust all: Optimization was performed across all five data-
sets with GTV geometry travel. Only the maximum dose to lung,
minimum PTV coverage and maximum PTV dose were included
as robust objectives. All other objectives were only optimized on
the central travel dataset.
5. Plan robust ext: Optimization was performed as per Robust All
with the exception that only the central, the 2 cm superior, and
the 2 cm inferior geometries were included in robust objectives.
The intention of this test was to determine if the exclusion of
intermediate breathing cycles would improve optimization speed
without a reduction in the plan quality.
6. Plan robust values: Robust optimization was performed with
user-defined geometry offsets in the superior and inferior direc-
tion rather than across several scans. Robust optimization
F I G . 2 . Shifts of GTV insert across
scans. 1: Lung Tissue Insert, 2: GTV Wax
Insert, 3: Isocentre, 4: Gafchromic Film, 5:
Chamber insert, 6: Air Cavity.
F I G . 3 . Travel of GTV superior to inferior (left to right) across all five scans, and the average compiled dataset (far right). Note the full travel
of the GTV (red) is encompassed by ITV (maroon) geometry.
ARCHIBALD-HEEREN ET AL. | 107
objectives were maintained as per the Robust All plan. This
methodology offers the assessment of the potential of robust
planning in the absence of multiple CT datasets rather than the
conventional use of a uniform PTV expansion.
7. Plan lung override. Plans were optimized as per the methodology
by Wiant et al46 where by the ITV excluding the GTV on the free
breathing scan was overridden to an intermediate density. This
methodology was shown to provide significant improvements
over ITV optimization with the analytical anisotropic algorithm of
the Eclipse planning system (Varian Oncology Systems, CA, USA).
For this work a density override was set to 0.6 g/cm3 to corre-
late with a midpoint density between solid tissue and the sur-
rounding 0.2 g/cm3 lung.
Unless explicitly mentioned above, all plans were performed on
the central planning scan. Each scan relied on a dual arc VMAT
delivery of two 360°deliveries with the isocenter set to the centre
of the GTV in the primary scan. To prevent excessive modulation,
the leaf travel was limited to 0.5 cm/degree and the control point
spacing set to 4° as per clinical practice. Plans were planned for a
Varian iX iClinac with millennium MLC. Dose calculation was per-
formed on a 3 mm dose grid.
A further set of square 10 9 10 Ant-Post beams was added as a
standard reference-conditioned field to verify the accuracy of refer-
ence dose.
2.C | Optimization
Prior to planning a set of clinical goals were set for the acceptance
of plans. The goals were set arbitrarily to push the optimization sys-
tem and create difficult but achievable modulated plans. The evalua-
tion of clinical goals was performed solely on the planning
(offset = 0 cm) geometry. These were loosely guided by common
goals for typical dose and fractionation levels at the centre.
A list of the applied clinical goals is provided in Fig. 4.
For robust planning the motion of the ITV becomes redundant
as the travel of the GTV is encompassed within the optimization sys-
tem rather than a geometry expansion. For this reason, the ITV cov-
erage was not optimized for robust plans.
Plans were accepted when they met the criteria set out in Fig. 4.
In some scenarios these goals were exceeded. As plan quality was
not a metric in this study, once clinical goals were satisfied the
optimization ceased. As a result, the variation between final plan
quality among all plans was negligible.
A concerted attempt was made to meet all clinical goals in each
plan. In situations where goals could not be met, the plan was opti-
mized such that the max dose control was the least critical. All but
one plan of 14 (2 9 7 optimization techniques) met all clinical goals
which exceeded the max constraint by <0.05% of TD.
For each case the final calculated dose, DVH curves, and dose
statistics were recorded.
2.D | Calculation on breath cycle
Each of the completed plans was recalculated on each phase of the
4DCT datasets. In Raystation, for CT datasets with identical UID and
frame of reference, the plan isocenter is intrinsically correlated
between datasets by the common DICOM co-ordinates, providing
consistency in set-up with the exception of the moving lung insert.
Comparisons were then made between DVH curves, organ statistics,
and 2D dose distributions in each geometry. As the images were not
taken as 4D binned sets calculation accuracy was reviewed on a per
set basis independent of phase weightings.
2.E | Measurements
Each of the created plans were exported to Mosaiq 2.4 (IMPAC, CA,
USA). Plans were imported as per standard clinical practice and
delivered to the CIRS phantom in the corresponding breath cycle
phantom positions.
2.E.1 | Chamber measurements
For each plan two sets of chamber measurements were taken; one
at the central tumor and one at the inferior lung. Chamber measure-
ments at lung position were taken simultaneously with film measure-
ments at a distance 1.5 cm inferior to the film insert as shown in
Fig. 5 in the film plans. Central tumor measurements were taken
with the A1SL chamber insert described above in separately opti-
mized plans at the planned and offset positions as per film measure-
ments. Dosimetry measurements were taken with Exradin A1SL
(Standard Imaging, WI, USA) and PTW TN31010 Semiflex chambers
with active volumes of 0.057 cm3 and 0.125 cm3 respectively.
A PTW Webline electrometer (PTW, Freiburg, Germany), was utilized
for charge collection and all corrections were applied as per the for-
malism of IAEA TRS 398 v1256 to convert the chamber reading into
dose. All measurements were repeated twice. Before each measure-
ment the chamber position was verified with on-line Cone beam
images to the original scans in RayStation.
Calculated chamber doses were determined by average dose to
accurately modeled active volumes of the chamber geometries.
Uncertainty for comparison was limited to positional errors of vol-
ume placement. As each delivery was imaged prior with CBCT posi-
tional accuracy of 1 mm, errors were determined on a worst case
2 mm geometric set-up error. Taking variations in average dose byF I G . 4 . Plan clinical goals for optimization.
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shifting the active volume 2 mm in all planes across all plans resulted
in an uncertainty of planned chamber dose of 1.5% as a result of
small positional errors. Measurements in low density material with
Ion chambers are known to suffer from perturbation effects57 from
the replacement of lung tissue and the nonwater equivalence the
chamber walls, stem, and central electrode. As no current 6MV per-
turbation factors are published for the A1DSL chamber, all lung mea-
surements were taken with the PTW Semiflex chamber. Work by
Araki58 modelling the chamber with Monte Carlo calculations
showed perturbation correction factors as much as 3% for 3 9 3
fields and 1% for 5 9 5 fields in 6MV beams. The predominant
size of beams used in this work was approximately 5 9 3 cm and
thus 3% represents a worst case scenario in the subsequent mea-
surements. These perturbation factors were not applied to the final
measurements, but were included within the total chamber uncer-
tainty of 4.5%. Chamber measurements in more standard condi-
tions, in the tumor measurements, were accurate within a more
typical uncertainty of 1.5%, accounting for standards calibration,
temperature, and pressure uncertainties.
Total uncertainty, inclusive of calculation and measurement,
when summated in quadrature was 2.1 and 4.7% for tissue and lung
measurements respectively.
2.E.2 | Film measurements
As per the chamber measurements, all film measurement plans had
verification cone beam CT images taken for each breath cycle to
ensure correct film orientation to within 5° and  1 mm. The dose
attributed to the film from the CBCT acquisition was considered
negligible when analysing distributions of 6 Gy fractions and was
not accounted for in the comparisons. Gafchromic EBT3 film (Ash-
land Advanced Materials, NJ, USA), of which the accuracy has been
verified in numerous works,59–63 was used for measurements. Film
scanning was performed with an Expression 10000XL flatbed scan-
ner (Epson Group, Nagano, Japan) at 24 hr post irradiation.
Dosimetric accuracy was verified using chamber measure-
ments and 1D gamma analysis of film insert dosimetry. Gamma
analysis was performed with the widely used 3%/3 mm criteria
but limited to the superior inferior 1D distribution as a limita-
tion of the phantom and possible film width. This analysis is
considered acceptable for the work as the area under investiga-
tion is contained in the superior and inferior geometries, with
no density changes in the remaining directional components. To
ensure precision of film against the 2D dose planes, all distribu-
tions exported from the TPS were recalculated with a 2 mm
dose grid for comparison. The effect of grid resolution has been
shown in previous work45 in areas of dose build up and density
junctions.
3 | RESULTS
3.A | Chamber measurements
The results of comparison between calculated (in the associated
tumor geometry) and delivered doses to the chamber volumes are
shown in Tables 1 and 2. For clarity individual reading variation is
not provided, however, across all chamber readings variation per
measurement were <0.3%.
3.B | Lung measurements
3.B.1 | Film Measurements
Analysis of distributions along the length of travel of the primary
tumor site are presented in Table 3. Results are presented as the
percentage of points passing the gamma analysis at a 3%/3 mm tol-
erance.
3.B.2 | Tumor dose distributions
There is strong agreement between both film and chamber dosime-
try and calculations performed in each breathing phase. Given this
strong agreement the planning system was utilized to quantify the
dose distribution effects to the tumor and lung due to breathing
motion.
F I G . 5 . Position of chamber measurements for (a) GTV and (b) lung measurements.
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Tumor dose variations for the various planning techniques are
shown in Figs. 6 and 7. Variations from the central planned dose are
displayed as a demonstration of the robustness of both coverage and
resultant dose escalation from the investigated effect of tumor motion.
Adequate tumor coverage (>95%) was achieved across all breath-
ing cycles in all plans with the exception of the GTV and Lung over-
ride plans. Both optimization techniques resulted in substantial
reduction in tumor coverage with tumor motion.
TAB L E 1 Percentage variation in chamber measured dose from calculated phase dose for the tumor position in each phase of the 4DCT
dataset.
Tumor chamber dose
Dose variation from planned
Inferior 2 cm Inferior 1 cm Plan geometry Superior 1 cm Superior 2 cm Average variation
10 9 10 1.9% 0.7% 0.7% 0.8% 2.3% 1.3%
GTV 5.1% 1.0% 0.5% 2.2% 3.7% 2.5%
ITV 0.5% 1.9% 0.9% 1.9% 0.8% 1.0%
Average 3.3% 3.2% 3.0% 1.5% 0.8% 1.4%
Lung override 5.7% 1.7% 1.8% 0.9% 1.0% 1.4%
Robust all 1.2% 0.2% 1.8% 0.1% 0.3% 0.0%
Robust extremes 2.4% 1.0% 2.4% 0.9% 0.8% 0.2%
Robust values 0.5% 1.4% 0.5% 0.0% 0.1% 0.2%
Average variation 0.7% 0.3% 0.5% 0.6% 0.5%
Standard deviation 3.3% 1.7% 1.7% 1.2% 1.7%
TAB L E 2 Percentage variation in chamber measured dose from calculated phase dose for the lung position in each phase of the 4DCT
dataset.
Lung chamber dose
Dose variation from planned
Inferior 2 cm Inferior 1 cm Plan geometry Superior 1 cm Superior 2 cm Average variation
10 9 10 3.2% 1.3% 1.6% 0.2% 0.3% 0.7%
GTV 0.1% 0.5% 3.1% 3.9% 3.1% 1.9%
ITV 0.6% 3.2% 4.2% 2.8% 2.2% 1.3%
Average 0.7% 2.6% 2.7% 1.6% 1.6% 0.8%
Lung override 0.6% 0.9% 1.2% 2.1% 2.2% 0.6%
Robust all 0.8% 2.0% 3.6% 1.8% 1.6% 1.9%
Robust extremes 1.4% 1.2% 2.6% 1.5% 1.0% 1.1%
Robust values 0.7% 2.9% 2.0% 2.7% 2.1% 0.9%
Average variation 0.7% 1.0% 2.3% 2.0% 1.8%
Standard Deviation 1.4% 1.9% 1.6% 1.2% 0.9%
TAB L E 3 1D Gamma analysis of calculated vs film measured central axis dose profiles in plane of travel.
Plan
3%/3 mm gamma result (% points passed)
Inferior 2 cm Inferior 1 cm Plan geometry Superior 1 cm Superior 2 cm Average gamma Standard deviation
10 9 10 95.8 100 98 99 98.7 98.3 1.6
GTV 93 91 99.7 100 100 96.7 4.4
ITV 100 100 91.7 96.9 98.8 97.5 3.5
Average 99.9 95.7 100 96.7 88.2 96.1 4.8
Lung override 93.7 96.7 81.4 96.7 99.1 93.52 7.0
Robust all 97.7 97.5 91.3 97 100 96.7 3.2
Robust ext 89.3 91.6 93.5 95.5 100 94.0 4.1
Robust values 97 99.9 100 95.3 98.2 98.1 2.0
Average gamma 95.8 96.6 94.5 97.1 97.9 96.4
Standard deviation 3.7 3.6 6.4 1.6 4.0 1.8
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Tumor dose variation was larger in the travel toward air in com-
parison to lung, resulting in variations in maximum dose from plan of
9, 5, 8% into lung and 26, 22, and 21% into air for GTV, ITV, and
average plans respectively.
3.B.3 | Lung dose distributions
Measurements of lung maximum and mean dose variations are dis-
played in Figs. 8 and 9.
The GTV plan resulted in the lowest mean dose to the lung, a
natural result of the reduced length of treatment. Of the remaining
methodologies the ITV, lung override, and robust optimization across
all datasets resulted in a decrease in mean lung dose of over 1.5 Gy
from the average dataset methodology.
The average plan methodology produced the highest lung max
dose in all breathing cycles. In all but one case the ITV plan method-
ology produced higher lung maximum doses than the robust opti-
mization methodologies.
4 | DISCUSSION
4.A | Dose accuracy
Of the 40 central GTV measurements the mean variation from calcu-
lated dose was 0.0%  2.3%. The GTV plan showed the poorest
agreement with an average 2.5% dose escalation from planned and a
significant 5.1% dose discrepancy in the 2 cm inferior geometry.
Measurement of lung doses shows excellent agreement with cal-
culation. Over all measurements the average discrepancy between
measured and calculated dose was 1.1%  1.9%. All chamber mea-
surements taken showed agreement within the uncertainty range
6%, with a maximum discrepancy of 5.7%.
1D gamma analysis results for all 40 delivered breathing cycles
are shown in Table 3. Excellent agreement is seen across all dose
profiles with an average of 96.4% of all points passing the 3%/3 mm
criteria, and only 2 of 40 plans resulting in a pass rate under 90%.
The worst performing result was recorded with the lung override
technique in the central geometry.
F I G . 6 . Planned 98% coverage of GTV
with tumor displacement.
F I G . 7 . Planned GTV 2% Dose with
tumor displacement.
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The results demonstrate that the TPS accurately models the
delivered dose in the offset geometries for all plans. This provides
the foundation for analysis of plans primarily through the Raystation
planning system calculated doses.
4.B | Plan dosimetry
The gamma analysis curves in Fig. 10 show the agreement
between planned and delivered dose for the 2 cm offset toward
the optimized air cavity for three different plans, verifying the
effect is a real delivery consequence rather than solely computa-
tional error. It can be seen that the 130% dose escalation
greater than that planned seen in the GTV and ITV plans are
avoided in the robust optimization plan. This is an extreme sce-
nario in which a 2.5 cm diameter cylinder of air resides adjacent
to the tumor volume, and therefore may be clinically unrealistic.
However, results in Fig. 11 show a decreased, yet similar effect
with optimization to lung (Plan GTV and ITV inferior shifts). The
results show parallels to previous published literature64 demon-
strating large increases in max doses when optimizing to lung
volumes.
A possible explanation for the significant dose escalation is pre-
sented by the authors. Work by Hunt et al65 showed reduced dose
in regions adjacent to a low density inhomogeneity where the low
density results in fewer electron interactions to deposit energy,
greater electron path length and a potential loss of electron equilib-
rium. As a result, in the optimization phase additional photon fluence
is required to provide equivalent dose to lung tissue and adjacent
soft tissue. The effect can be paralleled to the work performed by
both Thomas and Hoole44 and Byrne et al45 on the effects of opti-
mizing to the edge of skin/surface interfaces. The presented results
for internal optimization suggest that the effect is not limited to the
external surface, but may also be present at depth given the exis-
tence of sufficient air or low density lung inhomogeneity. The issue
occurs in phases where the GTV moves into a space optimized to air
or lung tissue, where the resultant increase in electron scattering
(i.e., build up and lateral scatter) due to significantly increased den-
sity results in dose escalation. When smaller targets traverse into
regions that were optimized to lung density, considerable differences
from the prescribed dose can occur. Such an effect is clearly repre-
sented in the DVH distributions presented in Fig. 11 for the ITV,
GTV and average dataset optimized plans.
F I G . 8 . Mean Lung dose with tumor
motion displacement.
F I G . 9 . Maximum (0.03 cm3 volume)
dose to lung (excluding GTV) with tumor
motion displacement.
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It should be noted that the effect does not appear to be linear in
nature. Dose escalations when optimizing to air, 0.2 g/cm3 lung, and




and qtissueqlung¼0:6 of 1000, 5, and 1.66. Dose escala-
tion is most exaggerated at edge of field boundaries. This suggests a
further effect at penumbra regions where lateral electron equilibrium
is lost as a result of multileaf collimator or jaw shielding.
Further work is required to determine the magnitude of dose
spikes in the presence of optimization to internal air cavities and low
density geometries. It is likely that the significance of such effects is
impacted by a range of factors including cavity size, density of sur-
rounding tissue, beam quality, and the presence of electron equilib-
rium conditions. Outside of the lung this effect may play a role in
other low density regions such as sinus cavities or air in rectum and
cervix patients.
In cases where large air cavities are included in the PTV within
lung, such as large airways at medial lung disease, there is a clear
and clinically significant dose variation. Robust optimization may be
one suitable solution for such scenarios. The distributions in
Figs. 6–9 show significant reductions in the impact of such effects in
the presence of tumor motion using robust optimization. All three
robust methodologies displayed significantly less variation in max
dose across the breathing cycle. Robust planning performed particu-
larly favorably in the presence of large tumor position variations,
both superiorly and inferiorly, compared with maximum variations of
25 and 8% for the GTV planning technique, 25 and 4% for the ITV
technique and 23 and 5% for the average dataset planning tech-
nique.
GTV and lung override techniques resulted in insufficient dose
coverage of the target over the full range of travel. Whilst this is
expected for the GTV plans, this result suggests that a lung override
technique is suboptimal when tumor motion is large. All other plans
provided suitable coverage to the tumor across the entire motion.
For the average density datasets and ITV plans this coverage was
achieved at the cost of large dose variations in the doses to the
GTV along its travel. In contrast, robust plans showed stable mean
and max lung doses across all tumor breathing cycles. With regards
to tumor dose distribution and lung doses the robust plans provided
more stable dose distributions across all positional offsets, allowing
for tumor dose coverage without large dose escalation.
Whether such an improvement is clinically significant is difficult
to ascertain. The dose escalation of in-air optimization for GTV, ITV
and average datasets in the superior offset geometries would be
considered clinically significant in almost all cases at over 20%
F I G . 10 . 1D dose profiles and gamma analysis for 2 cm sup plans of (a) Robust All, (b) GTV and (c) ITV optimization methodologies.
F I G . 11 . Dose Volume Histogram
distributions of dose to the primary tumor,
ipsilateral lung, and heart through
breathing cycles 2 cm superior (air
optimization) and inferior (lung
optimization) for (a) GTV plans (b) ITV
plans (c) Robust planning across all scans
and (d) Average datasets.
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variation. For the lung based optimization with dose escalations
between 4 and 8% the blurring of dose across the breathing cycle
will lead to a reduction in such a maximum. It is not the aim of this
paper to produce weighted doses in line with breathing cycle such
as in work by Bortfeld et al.42 However, given a sinusoidal breathing
distribution such as outlined by Chan et al.51 it is not unreasonable
to expect the probability of the tumor to be in the full extents of
motion to around 30–40%, providing a dose variation over the
breathing cycle of 3–4%. These motions also represent an extreme
at a total of 4cms travel. At 1 cm superior and inferior the dose
escalation results were significantly reduced, though still consider-
able for air optimization.
Robust optimization may have a considerable role to play in
breath hold techniques given the extreme dose escalation seen in
the GTV cases, even in the presence of smaller tumor motion. Fur-
ther dose calculation effects may arise as a result of increased air
pressure in the lungs and a reduced overall lung tissue density. The
optimization across a breath hold and 1–2 maximum inhale 4DCT
bins in planning may provide stable dose distributions, and reduced
treatment times whilst maintaining tissue sparing.
4.C | Further considerations
This study has intentionally focused on an extremely simple repre-
sentation of the problem of optimization and tumor motion. Further
to the target motion itself, the travel of surrounding tissue may have
an equally large impact on the stability of the intended planned
DVH distributions. Cases in which the motion of the heart traverses
across several VMAT segments may have a significantly larger
impact on organ and tumor dose than the effect of optimization at
the tissue-low density border and should be further investigated to
assess the full potential advantages of robust optimization to clinical
patients.
Implementation of robust optimization across all or partial 4DCT
scans provides the fastest optimization and most theoretically pleas-
ing solution. In this study, each GTV was provided with a 5 mm PTV
expansion to account for slight changes in tumor motion and daily
setup uncertainties as documented by Ruben et al.9 Work by
McCann66 and Chan51 have shown that such uncertainties can be
accounted for with reduced tissue doses by escalating dose to the
edges of the GTV. Therefore, a potentially ideal solution for future
investigation is the optimization across the 4DCT dataset with inten-
tional dose escalation at the maximum extent of travel. This imple-
mentation in a current ITV approach may lead to even greater dose
inhomogeneity than found in this work, and as such care should be
taken.
5 | CONCLUSION
A range of optimization techniques, including implementation of
robust optimization, were used to create VMAT deliveries for mov-
ing targets in a lung phantom. All plans have been recalculated in
the RayStation treatment planning system across five breathing
cycles.
Chamber and film measurements were used to verify the accu-
racy of the RayStation calculations for each of the plans in each of
the five breathing cycles. The chamber measurements show excel-
lent agreement with the calculated dose with an average discrepancy
of 0.0%  2.3% in the tumor and 1.1%  1.9% in lung. Gamma
analysis performed between calculated and measured film dosimetry
resulted in an average pass rate of 96.4% for 3%/3 mm criteria, with
2/40 comparisons recording pass rates under 90%.
Plans optimized using minimum dose constraints to low density
volumes resulted in large dose escalations once occupied by the
moving tissue density target. Dose escalations of up to 22% above
planned calculation doses were noted in plans optimized to low den-
sity ITVs and average density datasets. Where possible target vol-
umes should exclude air cavities in the lung such as bronchial
airways.
Plans in which the ITV was overridden to an intermediate density
resulted in reduced dose escalation but an under dose to the GTV
through the breathing cycle.
Robust optimization provides greater stability in dose for large
tumor motion. In the presence of smaller tumor motion of <1 cm,
the effect was less significant. In areas where the PTV covered an
air volume. Tumors with large motion and large density variations in
surrounding tissue may result in significant improvements in dose
stability with implementation of robust optimization.
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